Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Trims Position in Amgen Inc. $AMGN

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 9.4% during the 4th quarter, HoldingsChannel reports. The fund owned 52,030 shares of the medical research company’s stock after selling 5,429 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Amgen were worth $18,279,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock valued at $15,204,047,000 after purchasing an additional 165,281 shares during the last quarter. Capital International Investors increased its holdings in shares of Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors increased its holdings in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after buying an additional 1,935,876 shares during the last quarter. Capital Research Global Investors raised its position in shares of Amgen by 2.7% during the 3rd quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock valued at $1,335,168,000 after buying an additional 122,631 shares during the period. Finally, Invesco Ltd. lifted its holdings in Amgen by 6.6% in the third quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company’s stock valued at $1,260,668,000 after acquiring an additional 277,031 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 0.3%

Shares of NASDAQ AMGN opened at $345.92 on Thursday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock has a market capitalization of $186.69 billion, a PE ratio of 24.31, a PEG ratio of 3.61 and a beta of 0.47. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The stock has a fifty day simple moving average of $361.59 and a 200-day simple moving average of $338.73.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period last year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts forecast that Amgen Inc. will post 22.18 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s payout ratio is 70.84%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AMGN. UBS Group increased their price objective on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Wells Fargo & Company increased their price target on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Mizuho raised their price objective on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Finally, Freedom Capital lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $356.62.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Guggenheim nudged its price target up to $351 (from $347) ahead of earnings, citing an updated model — a modest upgrade that supports the stock’s near-term upside. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Positive Sentiment: Increased retail/investor attention reported by Zacks highlights AMGN as a “trending” stock — that can boost flows and short-term liquidity. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Amgen announced the retirement of CTO David M. Reese (effective June 30) and said it will realign leadership to integrate biology and technology — a purposeful transition but without immediate operational red flags. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: Canaccord Genuity initiated coverage with a Hold recommendation — indicates cautious analyst stance but not a downgrade signal. Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Neutral Sentiment: Bernstein issued a Hold on AMGN, echoing a cautious consensus among some sell-side analysts despite Amgen’s solid fundamentals. Amgen (AMGN) Receives a Hold from Bernstein
• Negative Sentiment: Multiple insiders sold about US$4.1M of AMGN stock over the past year — a signal some investors view as caution from management-level holders. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.